"We look forward to assembling a team that can provide objective feedback and guidance on Regenicin's efforts to develop and deliver breakthrough treatments for chronic burns and wounds," says Randall McCoy, CEO of Regenicin. "Currently we have identified our key candidates and will announce them individually upon full approval by our board of directors." Regenicin expects to have the full Scientific Advisory Board is in place within the next ninety days.
About Regenicin, Inc.
Regenicin, Inc. is a development stage company focusing on next-generation tissue-engineered skin substitutes to restore the qualities of healthy human skin. Regenicin is a publicly traded company, with headquarters in Little Falls, NJ. Additional information can be found in the company's filings with the Securities and Exchange Commission located at www.sec.gov.
Safe Harbor Statement
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a number of uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission. The company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
SOURCE Regenicin(TM), Inc.